Ponatinib - CAS# 943319-70-8 size:2mg solid WDR5-0103 was used at 10

WDR5-0103 was used at 10 µM final concentration in various in vitro assays

1007/s10741-018-9757-1

MMAF inhibits anaplastic large cell lymphoma Karpas 299

CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling molecules such as RAF

as well as the expression of a range of other Hif-1α-dependent genes

Ponatinib - CAS# 943319-70-8 size:2mg solid WDR5-0103 was used at 10Ponatinib, CAS No. 943319 70 8, is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor AP24534 inhibits unmutated and all mutated forms of Bcr Abl, including T315I, the highly drug therapy resistant missense mutation of Bcr Abl. This agent also inhibits other tyrosine kinases including those associated with vascular